A study reveals that, when anti-VEGF agents are used to treat cancer, the hypoxia due to excessive vessel regression will cause some cells (MDSCs, M2-TAMs, as well as Tregs) associated with immunosuppression to stimulate angiogenesis via upregulating the expression of pro-angiogenic factors, which results in resistance to anti-VEGF therapy (75) (Figure 2). Here, VEGFA is linked to cancer.